A Study of Patients with Polycythemia Vera In US Clinical Practices

Overview

About this study

The purpose of this study is to assess to clinical burden and resource use associated with the management of patients with polycythemia vera.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age ≥ 18 years
  • Diagnosis of Polycythemia Vera (PV)
  • Willing and able to provide written informed consent
  • Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
  • Under the supervision of a physician for the current care of PV including but not limited to
    • Watchful waiting
    • Acetylsalicylic acid (ASA) 81mg or greater
    • Antithrombotic therapy
    • Phlebotomy
    • Hydroxyurea 
    • Interferon (recombinant or pegylated)
    • Busulfan
    • Anagrelide

 

Exclusion Criteria

  • Participation in an active clinical trial in which the study treatment is blinded
  • Life expectancy < 6 months
  • Diagnosis of myelofibrosis (MF) [including primary MF, post-PV MF, or post-essential thrombocythemia MF]
  • Diagnosis of secondary Acute Myeloid Leukemia
  • Diagnosis of Myelodysplastic Syndrome
  • History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months
  • Splenectomy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jeanne Palmer, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available